Neurocrine Biosciences projects $6 billion revenue by 2031 with expanding drug portfolio

Neurocrine Biosciences reported $959 million in revenue for the second quarter of 2026, marking a 39% increase compared to the same period last year, according to The Motley Fool.

The company's flagship drug, Ingrezza, remains its largest revenue source, with sales growing by 15%, The Motley Fool noted.

Beyond its original focus on neurological diseases, Neurocrine is expanding its portfolio with two late-stage drug candidates targeting depression and schizophrenia, which are expected to reach important clinical milestones in 2027.

By 2031, Neurocrine could become a significantly larger pharmaceutical company, potentially generating between $6 billion and $7 billion in annual revenue, The Motley Fool projected.